Identification of predictive parameters for 6-MP response in AML patients

Identification of predictive parameters for 6-MP response in AML patients - Prognostic parameters for 6-MP treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31997

Enrollment

Registered

2008-12-04

Start date

2008-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age >18 years - diagnosed with (relapsing) AML not eligible for intensive chemotherapy

Exclusion criteria

Exclusion criteria: Ineligible to perform proposed test

Design outcomes

Primary

Measure	Time frame
- AML blasts cells will be analyzed for the expression of drug-resistant parameters, nuclear receptor and the in vitro responsiveness to 6-MP. - Facs analyses will be performed to define the changes in lymphoid markers during treatment of 6-MP. - Treatment response of patients will be defined by improvements in peripheral blood cell counts and bone marrow composition.	—

Countries

Netherlands

Outcome results